December 2020 FDA Recall Drug by Morton Grove Pharmaceuticals, Inc.
D-0174-2021 - Failed Impurities/Degradation Specification

This Class II drug recall was voluntarily initiated by Morton Grove Pharmaceuticals, Inc. on December 9, 2020 for the product Drug. The FDA reported the reason for recall as failed impurities/degradation specification. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0174-2021

Reason for Recall
Failed Impurities/Degradation Specification: OOS for the following - unknown degradant/impurity, 4-chorobenzophenone, and for total impurities.
Initiated
12-09-2020
Reported
12-30-2020
Quantity
127,392 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Morton Grove Pharmaceuticals, Inc.
Nationwide USA and Puerto Rico
Hydroxyzine Hydrochloride Oral Solution, USP (Syrup), 10 mg/5 mL, packaged in a) 4 fl oz (118 mL) bottle, NDC 60432-150-04, b) 1 pint (473 mL), NDC 60432-150-16, Rx Only, Manufactured By: Morton Grove Pharmaceuticals, Inc., Morton Grove, IL 60053

Batch or Lot Expiration Information

Lot# : a) UU1328, Exp 10/21; b) UU1207, Exp 07/21; UU1326, Exp 09/21; UU1327, Exp 10/21.